Detalhe da pesquisa
1.
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Haematologica
; 105(4): 1032-1041, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31296574
2.
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Int J Cancer
; 144(11): 2762-2773, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30468254
3.
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
Haematologica
; 102(11): e447-e451, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838994
4.
Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.
Sci Rep
; 7(1): 13946, 2017 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29066743
5.
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 23(6): 1493-1505, 2017 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27637890
6.
Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Clin Cancer Res
; 20(13): 3458-71, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24799524